• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Faron Pharmaceuticals

0.49 EUR-0.21 %30/7 14:15
5,750 following

FARON

First North Finland

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Dividend
Investor consensus
Compare
-0.21 %
+2.64 %
+8.12 %
-73.92 %
-75.65 %
-77.54 %
-84.83 %
-89.56 %
-85.44 %

Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.

Read more
Market cap
110.75M EUR
Turnover
30.03K EUR
P/E (adj.) (26e)
-4.71
EV/EBIT (adj.) (26e)
-5.42
P/B (26e)
84.34
EV/S (26e)
25,763.13
Dividend yield-% (26e)
-
Coverage
Recommendation
Buy
Target price
0.75 EUR
Updated
2026-03-11
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 2026-03-12

Latest extensive report

Released: 2022-08-23

Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types

Forum discussions
Zeidan provides a review of over an hour in an IACH (International Academy for Clinical Hematology – a non-profit academic organization focused on education) webinar Post-Congress Webinars – International Academy for Clinical Hematology (IACH) on what’s new in AML/MDS from EHA/ASCO...
7/27/2026, 2:30 PM
by Vino Pino
34
Now that is exactly what happened. A truly great thing. Faron Inside Information: Faron announces encouraging first overall survival data... Faron Pharmaceuticals Ltd | Company announcement | July 27, 2026 at 09:00:00 EEST Inside Information: After a median follow-up of 14.9 months...
7/27/2026, 6:25 AM
by jukkamu
21
First-line results were reported for the first time; the groups cannot be compared. The press release states that n=21. TP53 mutations were present in 48%, meaning 10 patients. Of those whose allelic status could be determined, 67% were biallelic. Apparently, it could not be determined...
7/27/2026, 6:43 AM
by Vino Pino
19
They are not taking a stance on the entire dataset in relation to aza. They are only comparing the difficult TP53 group to the results from the recent past. For the easier TP53 mono-group and all others, the competition continues. It is always right to announce whenever a result ...
7/27/2026, 7:29 AM
by Vino Pino
16
Here are Antti’s comments regarding Faron’s recent release On Monday, Faron published its first analysis of overall survival (OS) data from the BEXMAB study. The analysis concerns frontline patients with higher-risk myelodysplastic syndrome (HR-MDS). According to the early-stage ...
7/28/2026, 7:07 AM
by Sijoittaja-alokas
15
The press release didn’t actually state anything like that about the number of survivors: Survival follow-up is ongoing, and several patients remain alive and under follow-up, providing the opportunity for further maturation of the dataset over time. mOS could be determined for biallelic...
7/27/2026, 8:06 AM
13
How on earth can any conclusions be drawn regarding aza when 18 subjects are still alive and their results continue to improve for who knows how long (ref OS)? Is this reporting in accordance with the study protocol, or an attempt to boost a “lifeless” Faron in the middle of summer...
7/27/2026, 7:09 AM
by Jummijammi2
5
Read more on our forum
Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
26/8
2026

Interim report Q2'26

Faron reports first OS results from frontline MDS patients
Analyst Comment2026-07-28 08:33 by
Antti Siltanen

Faron reports first OS results from frontline MDS patients

Median overall survival has not been reached in 2/3 of patient groups after 14.9 months of follow-up.

Faron Pharmaceuticals
Regulatory press release2026-07-27 08:00

Inside Information: Faron announces encouraging first overall survival data from frontline higher-risk (HR) MDS patients in the BEXMAB phase 1/2 trial

Faron Pharmaceuticals
Regulatory press release2026-07-24 08:00

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Faron updated the status of investigator-initiated bexmarilimab studies
Analyst Comment2026-07-14 08:16 by
Atte Riikola

Faron updated the status of investigator-initiated bexmarilimab studies

The bexmarilimab cohort in the FINPROVE trial was discontinued, but the company's own blood cancer trials are moving forward.

Faron Pharmaceuticals
Press release2026-07-13 08:00

Faron Provides Update on Investigator-Initiated Trial Portfolio for Bexmarilimab

Faron Pharmaceuticals
Regulatory press release2026-07-01 12:00

Faron Pharmaceuticals Ltd: Grant of Options

Faron Pharmaceuticals
Regulatory press release2026-06-22 15:00

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals
Regulatory press release2026-06-17 15:30

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals
Regulatory press release2026-06-17 08:00

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals
Press release2026-06-16 14:58

Redeye: Faron Pharmaceuticals: Matured BEXMAB data from EHA and BEXERA update

Faron Pharmaceuticals
Faron's BEXMAB update provided additional information on response duration
Analyst Comment2026-06-16 08:15 by
Antti Siltanen

Faron's BEXMAB update provided additional information on response duration

According to the company, the Phase 2b BEXERA trial will start in H2'26.

Faron Pharmaceuticals
Regulatory press release2026-06-15 17:00

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals
Faron Pharmaceuticals EHA 2026
Webcast2026-06-15 15:00

Faron Pharmaceuticals EHA 2026

Faron Pharmaceuticals
Press release2026-06-15 08:00

Faron Presents Matured BEXMAB Data at EHA 2026 Confirming Durable Efficacy and Bone Marrow Reprogramming in HR-MDS

Faron Pharmaceuticals
Regulatory press release2026-06-11 16:05

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals
Regulatory press release2026-06-11 16:00

Faron Pharmaceuticals Ltd: Registration of Treasury Shares

Faron Pharmaceuticals
Regulatory press release2026-06-10 18:45

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals
Regulatory press release2026-06-08 18:30

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals
Regulatory press release2026-06-05 12:50

Faron Pharmaceuticals Receives Decision from Nasdaq Helsinki Disciplinary Committee

Faron Pharmaceuticals
Regulatory press release2026-06-04 14:00

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals